Alirocumab + statin therapy

Alirocumab + statin therapy has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Oct 23, 2026: “Effects of Early Alirocumab Plus Statin Therapy on Lipid Control and Vascular Endothelial Function After PCI in Patients With Coronary Artery Disease”.

Intervention

1 paper studies it4 findingsUpdated

1 new paper in 30 daysSee all 1 papers on alirocumab + statin therapy

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“The reductions in total cholesterol, LDL-C, and ApoB were greater in the combination group than in the comparison group”
Effects of Early Alirocumab Plus Statin Therapy on Lipid Control and Vascular Endothelial Function After PCI in Patients With Coronary Artery DiseaseResearch Square2026doi:10.21203/rs.3.rs-11185127/v1

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Humans1

What did studies of alirocumab + statin therapy find?

3

Studies of alirocumab + statin therapy measured 3 outcomes: creatinine, flow-mediated dilation and LDL-C.

Creatinine

no changein humans1

1 study
  1. Alirocumab + statin therapy was not clearly linked with creatinine in humans (Coronary artery disease after PCI; compared with the regimen without a PCSK9 inhibitor).

    “between-group differences in changes in creatinine and CK were not statistically significant (P = 0.373 and P = 0.335, respectively).”

    HumansCoronary artery disease after PCI; compared with the regimen without a PCSK9 inhibitor8 weeksn = 62

    Effects of Early Alirocumab Plus Statin Therapy on Lipid Control and Vascular Endothelial Function After PCI in Patients With Coronary Artery Disease

    Research SquarePreprint

More on Creatinine

Flow-mediated dilation

upin humans1

1 study
  1. Alirocumab + statin therapy is linked with better flow-mediated dilation in humans (Vascular subgroup with coronary artery disease after PCI; compared with statin monotherapy).

    “was associated with favorable changes in FMD and selected measures of arterial elasticity.”

    HumansVascular subgroup with coronary artery disease after PCI; compared with statin monotherapybrachial artery8 weeksn = 22

    Effects of Early Alirocumab Plus Statin Therapy on Lipid Control and Vascular Endothelial Function After PCI in Patients With Coronary Artery Disease

    Research SquarePreprint

LDL-C

downin humans1

1 study
  1. Alirocumab + statin therapy is linked with lower LDL-C in humans (Coronary artery disease after PCI; compared with statin monotherapy).

    “The reductions in total cholesterol, LDL-C, and ApoB were greater in the combination group than in the comparison group”

    HumansCoronary artery disease after PCI; compared with statin monotherapy8 weeksn = 62

    Effects of Early Alirocumab Plus Statin Therapy on Lipid Control and Vascular Endothelial Function After PCI in Patients With Coronary Artery Disease

    Research SquarePreprint

More on LDL-C

What is alirocumab + statin therapy linked with?

1

Studies link alirocumab + statin therapy with ALT.

ALT

downin humans1

1 study
  1. Alirocumab + statin therapy is associated with ALT in humans (Combination group with coronary artery disease after PCI; compared with baseline).

    “ALT and AST decreased from baseline in the combination group (P = 0.030 and P = 0.002, respectively)”

    HumansCombination group with coronary artery disease after PCI; compared with baseline8 weeksn = 22

    Effects of Early Alirocumab Plus Statin Therapy on Lipid Control and Vascular Endothelial Function After PCI in Patients With Coronary Artery Disease

    Research SquarePreprint

More on ALT

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months